• The share capital has increased by SEK 6,175.00 to SEK 982,742.65.
• The number of shares and votes has increased by 123,500 to 19,654,853 shares and votes.
• The dilution amounts to 0.6%.

The share warrants that have been exercised are in part constituted of Immunovia's incentive program for senior management according to decisions taken at the 2016 AGM, issued the same year.

For more information, please contact: 

Julie Silber

Investor Relations Director, Immunovia

Tel.: +46-79-3486277

Email: julie.silber@immunovia.com (mats.grahn@immunovia.com)

This is information that Immunovia is obliged to make public pursuant to the Swedish Act on Trade in Financial Instruments. The information was submitted for publication, through the agency of the contact person set out above, at 08.30 CET on September 30, 2019.

About Immunovia
Immunovia AB was founded in 2007 by investigators from the Department of Immunotechnology at Lund University and CREATE Health, the Center for Translational Cancer Research in Lund, Sweden. Immunovia's strategy is to decipher the wealth of information in blood and translate it into clinically useful tools to diagnose complex diseases such as cancer, earlier and more accurately than previously possible. Immunovia's core technology platform, IMMray™, is based on antibody biomarker microarray analysis. The company is now performing clinical validation studies for the commercialization of IMMray™ PanCan-d that could be the first blood-based test for early diagnosis of pancreatic cancer. In the beginning of 2016, the company started a program focused on autoimmune diseases diagnosis, prognosis and therapy monitoring. (Source: www.immunovia.com)

Immunovia's shares (IMMNOV) are listed on Nasdaq Stockholm. For more information, please visit www.immunovia.com.

###